Are you above the legal age to view this content in your province/state?

Home / Cannabis Stock Market / Canadian Cannabis Sales Reach $246.7M

Canadian Cannabis Sales Reach $246.7M

This story originally appeared on The fresh toast.

Canadian Cannabis Sales Reach $246.7M

Retail sales were negatively affected by COVID lockdowns, while new stores and lower prices provided a boost.

New data from Statistics Canada revealed that Canadian cannabis sales in March improved 65% year-over-year reaching CA$298.1 million ($246.7 million), reports New Cannabis Ventures.

According to the outlet, this was the “slowest year-over-year growth” since recreational sales in the country began in late 2018. First-quarter sales improved only 1.8% sequentially.

The data analytics provider, Hifyre IQ, had projected April sales would improve around 4% hitting CA$309 million. This implies a 73% growth from the same period of a prior year.

Retail sales were negatively affected by COVID lockdowns, while new stores and lower prices provided a boost.

Breaking down sales data by province, Ontario improved the most gaining 121% year-over-year. Sales in Alberta improved 10% from the same period of 2020 and in British Columbia 12%.

Cantor Fitzgerald’s Pablo Zuanic provided an update on sales growth and market share trends by company and province. Based on this, most of the biggest Canadian cannabis players such as Aurora Cannabis (NYSE:ACB), Canopy Growth (NASDAQ:CGC), Organigram (NASDAQ:OGI) and Tilray (NASDAQ:TLRY), had seen their best sales in Ontario.

Disclaimer

Investment Value Finders specializes in providing opinions and information on stocks to individuals who wish to receive them. Our reports are construed for information purposes solely and are distributed free of charge to individuals who wish to receive them.


Investment Value Finders does not promote, condone or advocate licit or illicit drug use. Investment Value Finders cannot be held responsible for materials or contests posted on its website pages, or pages to which we provide links, which promote, condone or advocate licit or illicit drug use or illegal activities.


DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE. We are not registered as a securities broker-dealer or an investment adviser. We are neither licensed nor qualified to provide investment advice.


Investment Value Finders occasionally receives direct compensation for hosting links (or other* advertisements) to third party content that may be subject to disclaimer pursuant to Section 17(b) of the Securities Act of 1933. For those instances where the link text contains company or stock-specific mention, we provide the following list of compensation received in order to ensure full disclosure and transparency.


Investment Value Finders is intended for those 21+ years of age only!

Check Also

FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition

FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition

Lucid Adds Potential for Neurodegenerative Disease Treatments and Mental Health in a Novel Way TORONTO–(BUSINESS …